SynthesisJournal of cancer research and clinical oncology2010
FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis.
Synthesis in Journal of cancer research and clinical oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnosis value of focal liver lesions with SonoVue®-enhanced ultrasound compared with contrast-enhanced computed tomography and contrast-enhanced MRI: a meta-analysis.Journal of cancer research and clinical oncology · 2011Pooled it
- Comparison of Diagnostic Performance of Three-Dimensional Positron Emission Mammography versus Whole Body Positron Emission Tomography in Breast Cancer.Contrast media & molecular imaging · 2017Trial
- Article
- PET Molecular Imaging in Breast Cancer: Current Applications and Future Perspectives.Journal of clinical medicine · 2024Review
- Impact on the long-term prognosis of FDG PET/CT in luminal-A and luminal-B breast cancer.Nuclear medicine communications · 2022Article
- Health-Related Suffering and Palliative Care in Breast Cancer.Current breast cancer reports · 2021Review
- The Evolving Role of FDG-PET/CT in the Diagnosis, Staging, and Treatment of Breast Cancer.Molecular imaging and biology · 2019Review
- Diagnostic and prognostic value of 18F-FDG PET/CT imaging in suspected recurrence of male breast cancer.Nuclear medicine communications · 2019Article
- [Multimodal imaging of breast cancer recurrence : Prospective intraindividual comparison ofDer Radiologe · 2017Article
- Quantitative Evaluation of Therapeutic Response by FDG-PET-CT in Metastatic Breast Cancer.Frontiers in medicine · 2016Article
- Depression and Resilience in Breast Cancer Patients.Open access Macedonian journal of medical sciences · 2015Article
- Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.European journal of nuclear medicine and molecular imaging · 2015Article
- The diagnostic value of 18F-FDG PET/CT in association with serum tumor marker assays in breast cancer recurrence and metastasis.BioMed research international · 2015Article
- Diagnosis and evaluation of gastric cancer by positron emission tomography.World journal of gastroenterology · 2014Review
- The utility of 18 F-FDG PET/CT for suspected recurrent breast cancer: impact and prognostic stratification.Cancer imaging : the official publication of the International Cancer Imaging Society · 2014Article
- Recent Trends in PET Image Interpretations Using Volumetric and Texture-based Quantification Methods in Nuclear Oncology.Nuclear medicine and molecular imaging · 2014Review
- Circulating Tumor Cells in Metastatic Breast Cancer: A Prognostic and Predictive Marker.Journal of patient-centered research and reviews · 2014Article
- Is symptom-oriented follow-up still up to date?Breast care (Basel, Switzerland) · 2013Review
- 99mTc-thymine scintigraphy may be a promising method in the diagnosis of breast cancer.Clinics (Sao Paulo, Brazil) · 2013Article
- Positron emission tomography for benign and malignant disease.The Surgical clinics of North America · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeBreast carcinoma is the most common cancer in female patients with a propensity for recurrence and metastases. The accuracy of ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI), scintimammography (SMM) and positron emission tomography (PET) in diagnosing the recurrent and/or breast cancer has never been systematically assessed, and present systematic review was aimed at this issue.
methodsMEDLINE and EMBASE were searched for articles dealt with detection of recurrent and/or metastatic breast cancer by US, CT, MRI, SMM or PET whether interpreted with or without the use of CT. Histopathologic analysis and/or close clinical and imaging follow-up for at least 6 months were used as golden reference. We extracted data to calculate sensitivity, specificity, summary receiver operating characteristic curves and area under the curve and to test for heterogeneity.
resultIn 42 included studies, US and MRI had highest pooled specificity (0.962 and 0.929, respectively); MRI and PET had highest pooled sensitivity (0.9500 and 0.9530, respectively). The AUC of US, CT, MRI, SMM and PET was 0.9251, 0.8596, 0.9718, 0.9386 and 0.9604, respectively. Results of pairwise comparison between each modality demonstrated that AUC of MRI and PET was higher than that of US or CT, p < 0.05. No statistical significance was found between MRI and PET. There was heterogeneity among studies and evidence of publication bias.
conclusionIn conclusion, MRI seemed to be a more useful supplement to current surveillance techniques to assess patients with suspected recurrent and/or metastatic breast cancer. If MRI shows an indeterminate or benign lesion or MRI was not applicable, FDG-PET could be performed in addition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.